Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of atezolizumab in relapsed/refractory mycosis fungoides/Sezary syndrome (PARCT)
2017-003680-35Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in cutaneous T-cell lymphoma (CTCL) and Sézary syndrome (SS), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Best overall response rate. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2017-003680-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003680-35.